A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults
Pharmaceutical companies have used experimental models of transient insomnia to assess the sleep-promoting effects of investigational drugs for over 40 years. These models have included the "first-night effect" model, a parallel-group design that assessed drug effects when sleep was recorded in normal, healthy subjects who slept in a new or novel environment for the [...]